Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere granted Chinese approval for generic Biapenem injection
Anxin is the first Biapenem injection approved for sale in China, and will be used for the treatment of serious infections. As is the case with first-to- market
Anxin is the first Biapenem injection approved for sale in China, and will be used for the treatment of serious infections. As is the case with first-to- market
Smarticles are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells. Steffen Panzner, founder and chief scientific officer
Seroquel is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive
A primary goal of the collaboration is to gain a deeper understanding of the connection between body composition, metabolic profile and health. GE Healthcare’s Lunar iDXA system, an
This trial is a 14 patient, single arm, open-label, dose-targeted, non-randomized, multi-centre trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Patients
Vartan Ghazarossian, president and CEO of StemCor, said: “The grant will be used to broaden our capabilities regarding the harvest of bone marrow, as well as the processing
This new product line enables researchers to facilitate the development of new therapeutics and vaccines and accelerates future drug screening processes. As part of the collaboration, additional variants
In repeated trials, monkeys were dosed with well-tolerated amounts of drug and survived a challenge of roughly 1000 times the minimum lethal dose. This level of infectious challenge
Circadin, the first melatonin agent approved by the European Medicines Agency (EMEA), is now available for the treatment of primary insomnia and is said to be the first
The Determine study, coordinated by researchers at Northwestern University and sponsored by St Jude Medical, is the first study to look at patients who already have had a